RTSN SEC Filings, Earnings & Splits

Retension Pharmaceuticals appointed Robert Wong as Vice President and Chief Accounting Officer effective November 2, 2026. Wong brings 30 years of accounting and finance experience, most recently at The Save Mart Companies and previously as CAO at Cytokinetics.

The B Group, Inc., B Group Capital LLC, and Branden B. Muhl filed a joint Schedule 13G indicating a passive ownership stake in Retension Pharmaceuticals, Inc. The filing includes only a joint filing agreement exhibit with no ownership percentage or share details disclosed.

A Schedule 13G was filed regarding Retension Pharmaceuticals, Inc. (RTSN), indicating a passive ownership position by an institutional or other holder. The filing text provided contains only the EDGAR directory listing and no substantive ownership details.

A Schedule 13G was filed regarding Retension Pharmaceuticals, Inc. (RTSN), indicating a passive ownership position by an institutional or other holder. The filing text provided contains only the EDGAR directory listing and does not include the substantive ownership details.

A Schedule 13D was filed regarding Retension Pharmaceuticals, Inc. (RTSN), indicating a reporting person has acquired a greater than 5% beneficial ownership stake with potential plans or proposals for the company. The filing details are not fully available in the provided text.

Retension Pharmaceuticals filed its Third Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws in connection with the closing of its initial public offering on October 13, 2026.